News

With the FDA approval of 2 of these products, which are indicated for recurrent Clostridioides difficile infection (CDI), a study reviewed which types of clinicians are prescribing them and the protocols in using them.

CDC recommends HCV testing in these populations as a critical step to achieving national priority of eliminating HCV.

Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.

The companies announced a licensing agreement on cefepime-taniborbactam.

ACON Laboratories’ Flowflex COVID-19 Antigen Home Test completed the premarket review pathway and is the first test indicated for use in children under 18.

This week read about virus testing, the dosing of one of the COVID-19 vaccines in the pediatric population, HAI grades in hospitals, and live biotherapeutic products in preventing recurrent CDI in older adults with comorbidities.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

Use of antiviral therapy was linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy.

With the addition of 2 new live biotherapeutic products, a clinician reviews the application, storage and administration techniques for them.

New data showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

S salivarius probiotic reduces relative abundance of nasopharyngeal otopathogens but not incidence of acute otitis media in children.

The Leapfrog Group finds there were improved health care-associated infection (HAIs) rates following an earlier spike during the acute phase of the COVID-19 pandemic.

The federal agency was made aware some health care providers had administered the full single dose vial of the vaccine, which contains “notably more” volume than the 0.25 mL volume indicated for children aged 6 months to 11 years.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment, ADS024.

With these infections being problematic, a newer antiviral offers an alternative option for these patients.

The Centers for Disease Control and Prevention (CDC) looked at outbreak-related deaths and found a majority of decedents had existing preexisting conditions.

This week's stories include study data on 2 RSV vaccines for seniors; an update on C diff therapies; looking at Ending the HIV Epidemic initiative; and a study on Paxlovid and Long COVID.

A patient with a history of lupus nephritis initially presented with right hand and arm symptoms that were attributed to a lupus flare. However, eight months later, the patient experienced increasing pain and edema in his right hand, leading to a diagnosis of Histoplasma tenosynovitis.

Drawing parallels between liver health and everyday choices, such as diet, alcohol consumption, and drug use, can help individuals take responsibility for their actions and their overall well-being.

This discussion revolves around diagnostics for viruses and best practices and challenges.

Two RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.

Learning about these barriers is the first step to overcoming them.

This market has seen a flurry of activity, as shown by a review of the latest agents.

The patient advocacy organization has events in place and is ready to launch its annual C diff awareness campaign.

Veterans Affairs (VA) study finds some reduction in post-COVID thromboembolic events with early use of nirmatrelvir-ritonavir but no protection against 30 other conditions.

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.

Imprecise language can fuel infodemics and misinformation and damage public trust.

A new study highlights the growing threat of drug-resistant pathogens, particularly in healthcare settings, and underscores the need for enhanced surveillance and intervention strategies to combat these emerging and resistant infectious diseases.

In this week's news, CDC sent out a health advisory to change the prescribing recommendations for the newer preventative respiratory syncytial virus (RSV) monoclonal antibody; a clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices; and antidepressants were associated with a greater risk of Clostridioides difficile infection (CDI).

A comparative study found that using linezolid in place of clindamycin in combination with vancomycin for the treatment of necrotizing soft tissue infections resulted in similar 30-day mortality rates but lower rates of acute kidney injury and composite adverse outcomes, suggesting the effectiveness and safety of linezolid as an alternative therapy.